Table 1.
Baseline characteristics of patients on definitive therapy with third-generation cephalosporin (3GC) versus other antimicrobial agents.
| Characteristic | Definitive 3GC Therapy a N = 65 |
Definitive Non-3GC Therapy a N = 316 |
p-Value |
|---|---|---|---|
| Age, y (median (IQR)) | 59 (46.5–68.0) | 60 (47.8–70.0) | 0.989 |
| Male | 32 (49.2) | 202 (63.9) | 0.027 |
| Weight, kg (median (IQR)) | 80 (71.0–102.3) | 85 (70.0–103.0) | 0.884 |
| Race/Ethnicity | 0.308 | ||
| Black | 33 (50.8) | 130 (41.4) | |
| White | 29 (44.6) | 175 (55.4) | |
| Other/Unknown | 3 (4.6) | 11 (3.5) | |
| Intensive Care Unit Admission | 19 (29.2) | 144 (45.6) | 0.016 |
| CrCl, mL/min (median (IQR)) | 45 (21.9–85.4) | 56 (28.7–86.7) | 0.036 |
| Penicillin/Cephalosporin Allergy | 8 (12.3) | 41 (13.0) | 0.884 |
| Charlson Comorbidity Index (median (IQR)) | 3 (2.0–6.0) | 4 (2.0–6.0) | 0.984 |
| Source of Infection | |||
| Central Venous Catheter | 17 (26.2) | 61 (19.3) | 0.213 |
| Urinary Tract | 15 (23.1) | 63 (19.9) | 0.568 |
| Skin- or Skin Structure-Related | 9 (13.9) | 35 (11.1) | 0.525 |
| Intra-Abdominal | 6 (9.2) | 34 (10.8) | 0.714 |
| Respiratory | 3 (4.6) | 42 (13.3) | 0.049 |
| Other | 6 (9.2) | 16 (5.1) | 0.237 |
| Unknown Source | 9 (13.9) | 76 (24.1) | 0.072 |
| Site of Acquisition | 0.275 | ||
| Hospital-Acquired | 27 (42.2) | 160 (50.6) | |
| Healthcare-Associated | 21 (32.8) | 102 (32.3) | |
| Community-Acquired | 16 (25.0) | 54 (17.1) | |
| Pitt Bacteremia Score (median (IQR)) | 2 (1.0–3.0) | 3 (1.0–4.0) | 0.043 |
| Adequate Empiric Therapy | 60 (92.3) | 291 (92.1) | 0.952 |
Abbreviations: 3GC, third-generation cephalosporin; IQR, interquartile range; CrCl, creatinine clearance. a Data reported as n (%) unless otherwise noted.